# Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

> **NCT00030641** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Genta Incorporated**

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** oblimersen sodium
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00030641
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00030641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00030641, "Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00030641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*